Tags

Type your tag names separated by a space and hit enter

Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention.
Oncology. 2006; 70(1):1-12.O

Abstract

Breast tumorigenesis is a continuum from preinvasive lesions to early breast cancer and advanced disease. In this article the data supporting the use of the aromatase inhibitor anastrozole in postmenopausal women across this continuum are reviewed. In advanced disease, anastrozole has a significant survival benefit and tolerability advantage compared with megestrol acetate when used as second-line treatment. As first-line therapy, anastrozole significantly prolongs time to progression compared with tamoxifen in women with hormone receptor-positive (HR+) disease. In the adjuvant setting, anastrozole has superior efficacy and tolerability compared with tamoxifen in newly diagnosed patients and those who have already received 2-3 years' prior adjuvant tamoxifen. Therefore, anastrozole should be considered a preferred treatment option for postmenopausal women with HR+ early breast cancer. Furthermore, anastrozole has preoperative efficacy in HR+ large or locally advanced tumors. Finally, anastrozole substantially reduces the incidence of contralateral breast cancer compared with tamoxifen in women with HR+ early breast cancer and, therefore, is a potential chemopreventive agent. Anastrozole is thus positioned to become the standard care for postmenopausal women with HR+ disease across the whole breast cancer continuum. Additional data from ongoing studies will further clarify the role of anastrozole across the continuum and answer outstanding questions regarding the optimal timing and duration of treatment.

Authors+Show Affiliations

Breast Cancer Research Institute - La Prandie, Valojoulx, France. jmnabholtz@hotmail.com

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16439860

Citation

Nabholtz, Jean-Marc. "Role of Anastrozole Across the Breast Cancer Continuum: From Advanced to Early Disease and Prevention." Oncology, vol. 70, no. 1, 2006, pp. 1-12.
Nabholtz JM. Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention. Oncology. 2006;70(1):1-12.
Nabholtz, J. M. (2006). Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention. Oncology, 70(1), 1-12.
Nabholtz JM. Role of Anastrozole Across the Breast Cancer Continuum: From Advanced to Early Disease and Prevention. Oncology. 2006;70(1):1-12. PubMed PMID: 16439860.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention. A1 - Nabholtz,Jean-Marc, Y1 - 2006/01/26/ PY - 2005/08/18/received PY - 2005/10/18/accepted PY - 2006/1/28/pubmed PY - 2006/3/31/medline PY - 2006/1/28/entrez SP - 1 EP - 12 JF - Oncology JO - Oncology VL - 70 IS - 1 N2 - Breast tumorigenesis is a continuum from preinvasive lesions to early breast cancer and advanced disease. In this article the data supporting the use of the aromatase inhibitor anastrozole in postmenopausal women across this continuum are reviewed. In advanced disease, anastrozole has a significant survival benefit and tolerability advantage compared with megestrol acetate when used as second-line treatment. As first-line therapy, anastrozole significantly prolongs time to progression compared with tamoxifen in women with hormone receptor-positive (HR+) disease. In the adjuvant setting, anastrozole has superior efficacy and tolerability compared with tamoxifen in newly diagnosed patients and those who have already received 2-3 years' prior adjuvant tamoxifen. Therefore, anastrozole should be considered a preferred treatment option for postmenopausal women with HR+ early breast cancer. Furthermore, anastrozole has preoperative efficacy in HR+ large or locally advanced tumors. Finally, anastrozole substantially reduces the incidence of contralateral breast cancer compared with tamoxifen in women with HR+ early breast cancer and, therefore, is a potential chemopreventive agent. Anastrozole is thus positioned to become the standard care for postmenopausal women with HR+ disease across the whole breast cancer continuum. Additional data from ongoing studies will further clarify the role of anastrozole across the continuum and answer outstanding questions regarding the optimal timing and duration of treatment. SN - 0030-2414 UR - https://www.unboundmedicine.com/medline/citation/16439860/Role_of_anastrozole_across_the_breast_cancer_continuum:_from_advanced_to_early_disease_and_prevention_ DB - PRIME DP - Unbound Medicine ER -